Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 3/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.56 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | IL2 | P60568 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018232 | 0.91 | STIM1 (0.69) | STIM1ORAI1ORAI2NAMPTGRM1 | |
| SCHEMBL16020560 | 0.86 | STIM1 (0.53) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL16018235 | 0.86 | STIM1 (0.53) | STIM1ORAI1ORAI2NAMPTGRM1 | |
| SCHEMBL16018187 | 0.85 | STIM1 (0.54) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL16018169 | 0.84 | STIM1 (0.53) | STIM1ORAI1ORAI2IL2MEN1 | |
| SCHEMBL16572267 | 0.84 | STIM1 (0.57) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL12155639 | 0.84 | STIM1 (0.60) | STIM1ORAI1ORAI2IL2MEN1 | |
| SCHEMBL12156041 | 0.83 | STIM1 (0.61) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL14885568 | 0.82 | STIM1 (0.55) | STIM1ORAI1ORAI2NAMPTGRM1 | |
| SCHEMBL16018231 | 0.82 | STIM1 (0.58) | STIM1ORAI1ORAI2IL2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856240-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20140256745-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256745-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.